Prothena Corporation (PRTA)

DUBLIN--(BUSINESS WIRE)---- $PRTA #Prothena--Prothena announced that Novo Nordisk communicated that they expect to advance coramitug into a Phase 3 program for ATTR-CM in 2025.

Prothena (PRTA 3.96%), a biotechnology company focused on developing therapies for neurodegenerative diseases, released its second quarter 2025 results on August 4, 2025. The period saw notably weaker...

Prothena (PRTA) came out with a quarterly loss of $1.86 per share versus the Zacks Consensus Estimate of a loss of $1.11. This compares to earnings of $1.22 per share a year ago.

DUBLIN--(BUSINESS WIRE)--Prothena today announced that it will report its second quarter and first six months of 2025 financial results on August 4, 2025.

Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.

DUBLIN--(BUSINESS WIRE)--Prothena announced that the Company has initiated an approximate 63% reduction in its workforce.

DUBLIN--(BUSINESS WIRE)---- $PRTA #prothena--Prothena announced partner Roche will advance prasinezumab into Phase III development in early-stage Parkinson's disease.

PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.

Prothena Corporation plc PRTA released data from the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis on Friday.

DUBLIN--(BUSINESS WIRE)--Prothena today announced the Phase 3 AFFIRM-AL clinical trial evaluating birtamimab in patients with AL amyloidosis did not meet its primary endpoint.